Role of Allogeneic Stem Cell Transplantation in Multiple MyelomaBRUNO, Benedetto; GIACCONE, Luisa; SORASIO, Roberto et al.Seminars in hematology. 2009, Vol 46, Num 2, pp 158-165, issn 0037-1963, 8 p.Article

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myelomaGIACCONE, Luisa; STORER, Barry; BRINGHEN, Sara et al.Blood. 2011, Vol 117, Num 24, pp 6721-6727, issn 0006-4971, 7 p.Article

Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairmentMORABITO, Fortunato; GENTILE, Massimo; PETRUCCI, Maria Teresa et al.Blood. 2011, Vol 118, Num 22, pp 5759-5766, issn 0006-4971, 8 p.Article

Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromesFERRERO, Dario; DARBESIO, Antonella; GIAI, Valentina et al.British journal of haematology. 2009, Vol 144, Num 3, pp 342-349, issn 0007-1048, 8 p.Article

Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acidFIORE, Francesca; CASTELLA, Barbara; NUSCHAK, Barbara et al.Blood. 2007, Vol 110, Num 3, pp 921-927, issn 0006-4971, 7 p.Article

Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: Evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypesCARRADINI, Paolo; LADETTO, Marco; BENEDETTI, Fabio et al.Journal of clinical oncology. 2004, Vol 22, Num 8, pp 1460-1468, issn 0732-183X, 9 p.Article

Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myelomaCORRADINI, Paolo; CAVO, Michele; RUSSELL, Nigel et al.Blood. 2003, Vol 102, Num 5, pp 1927-1929, issn 0006-4971, 3 p.Article

Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genesFERRERO, Simone; CAPELLO, Daniela; ZANNI, Manuela et al.Haematologica (Roma). 2012, Vol 97, Num 6, pp 849-853, issn 0390-6078, 5 p.Article

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myelomaPALUMBO, Antonio; AMBROSINI, Maria Teresa; BRINGHEN, Sara et al.Blood. 2007, Vol 109, Num 7, pp 2767-2772, issn 0006-4971, 6 p.Article

Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myelomaMATTA, Giorgia Maria Elena; BATTAGLIO, Silvano; DIBELLO, Cristiana et al.Clinical cancer research. 2007, Vol 13, Num 18, pp 5348-5354, issn 1078-0432, 7 p., 1Article

Time to first disease progression, but not β2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapyPALUMBO, Antonio; BRINGHEN, Sara; FALCO, Patrizia et al.Cancer. 2007, Vol 110, Num 4, pp 824-829, issn 0008-543X, 6 p.Article

Management of multiple myeloma with bortezomib : Experts review the data and debate the issuesDICATO, Mario; BOCCADORO, Mario; CAVENAGH, Jamie et al.Oncology. 2006, Vol 70, Num 6, pp 474-482, issn 0030-2414, 9 p.Article

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cellsCORRADINI, Paolo; DODERO, Anna; RAMBALDI, A et al.Journal of clinical oncology. 2004, Vol 22, Num 11, pp 2172-2176, issn 0732-183X, 5 p.Article

High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrenceTARELLA, Corrado; CUTTICA, Alessandra; PAVONE, Enzo et al.Cancer. 2003, Vol 97, Num 11, pp 2748-2759, issn 0008-543X, 12 p.Article

Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myelomaPALUMBO, Antonio; GIACCONE, Luisa; BERTOLA, Alessandra et al.Haematologica (Roma). 2001, Vol 86, Num 4, pp 399-403, issn 0390-6078Article

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalPALUMBO, Antonio; BRINGHEN, Sara; GRASSO, Mariella et al.Journal of clinical oncology. 2014, Vol 32, Num 7, pp 634-640, issn 0732-183X, 7 p.Article

Bortezomib, Melphalan, and Prednisone in Elderly Patients With Relapsed/Refractory Multiple Myeloma: A Multicenter, Open Label Phase 1/2 StudyPETRUCCI, Maria Teresa; LEVI, Anna; FOA, Robin et al.Cancer. 2013, Vol 119, Num 5, pp 971-977, issn 0008-543X, 7 p.Article

Long-term follow-up of myelodysplastic syndrome patients with moderate/severe anaemia receiving human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3: independent positive impact of erythroid response on survivalCRISA, Elena; FOLI, Cristina; PASSERA, Roberto et al.British journal of haematology. 2012, Vol 158, Num 1, pp 99-107, issn 0007-1048, 9 p.Article

Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized TrialPALUMBO, Antonio; CAVO, Michele; NOZZOLI, Chiara et al.Journal of clinical oncology. 2011, Vol 29, Num 8, pp 986-993, issn 0732-183X, 8 p.Article

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3DIMOPOULOS, Meletios; KYLE, Robert; AVET-LOISEAU, Hervé et al.Blood. 2011, Vol 117, Num 18, pp 4701-4705, issn 0006-4971, 5 p.Article

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trialPALUMBO, Antonio; LAROCCA, Alessandra; RUS, Cecilia et al.Haematologica (Roma). 2010, Vol 95, Num 7, pp 1144-1149, issn 0390-6078, 6 p.Article

Serum Free Light Chain Ratio, Total K/λ Ratio, and Immunofixation Results Are Not Prognostic Factors after Stem Cell Transplantation for Newly Diagnosed Multiple MyelomaGIARIN, Manuela M; GIACCONE, Luisa; SORASIO, Roberto et al.Clinical chemistry (Baltimore, Md.). 2009, Vol 55, Num 8, pp 1510-1516, issn 0009-9147, 7 p.Article

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis : the superior disease control of R-HDS does not translate into an overall survival advantageLADETTO, Marco; DE MARCO, Federica; GALLAMINI, Andrea et al.Blood. 2008, Vol 111, Num 8, pp 4004-4013, issn 0006-4971, 10 p.Article

Bortezomib or high-dose dexamethasone for relapsed multiple myelomaRICHARDSON, Paul G; SONNEVELD, Pieter; REECE, Donna et al.The New England journal of medicine. 2005, Vol 352, Num 24, pp 2487-2498, issn 0028-4793, 12 p.Article

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: Evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3CUTTICA, Alessandra; ZALLIO, Francesco; BOCCADORO, Mario et al.Cancer. 2003, Vol 98, Num 5, pp 983-992, issn 0008-543X, 10 p.Article